Vemurafenib Active in Iodine-Refractory Thyroid Cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Papillary thyroid cancer (PTC) can become refractory to radioactive iodine (RAI).
• Limited treatment options exist for advanced or refractory RAI-unresponsive PTC.
• BRAF mutations are implicated in thyroid cancer progression.

Purpose of the Study:

• To evaluate the efficacy and safety of vemurafenib in patients with RAI-refractory PTC.
• To assess response rates and disease control with BRAF inhibition.

Main Methods:

• A study involving patients with advanced, RAI-refractory PTC.
• Treatment with the BRAF inhibitor vemurafenib.
• Monitoring for tumor response and adverse events.

Main Results:

• Vemurafenib demonstrated activity, inducing partial responses and stable disease in a subset of patients.
• Approximately 65% of patients experienced serious adverse events.
• Adverse events included the development of squamous cell carcinomas.

Conclusions:

• Vemurafenib offers a potential therapeutic option for RAI-refractory PTC.
• The observed toxicity profile necessitates careful patient monitoring and management.
• Further research is warranted to optimize BRAF inhibitor therapy in this population.